Efficacy and safety of recombinant human activated protein C for severe sepsis

Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine. 2001;344(10):699–709.

A randomized, double-blind, placebo-controlled, multicenter trial showing that treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding.

 

View article abstract​

Average Content Rating
(0 user)
Please login to rate or comment on this content.
User Comments